Guided Internet-Based Treatment for Harmful Alcohol Use; eBehandling Alkohol
Condition(s) studied
Investigational drug(s) / intervention(s)
Therapy-guided internet-based treatment program: eBA is a guided internet-based treatment for problematic alcohol use, based on cognitive behavioural therapy and motivational interview. The patients get access to self-help modules with information, questionnaires, and tools useful in a process of reducing alcohol use. Questionnaires measuring changes in alcohol use, illicit drug use, physical and mental health, and quality of life are frequently answered. These questionnaires are an integrated part of the treatment program and are used by the therapist to monitor and adjust the treatment according to each patient. The patients use the results from the questionnaires to assess whether the treatment is helpful reaching the treatment goal. The patients are guided by a therapist, and they communicate using a system for written messages in the treatment program and/ or guided by telephone.
Study summary
Guided internet-based treatment for individuals with harmful alcohol use, eBehandling Alkohol (eBA), will be implemented as an experimental treatment option in five hospitals autumn 2024. Concurrently, a research project related to the effects of eBA will be conducted. Results from a pilot project show that treatment with eBA can help reduce alcohol use and improve mental health among people with harmful alcohol consumption. Similar results have been found in other international studies.
Many individuals with harmful alcohol consumption avoid seeking treatment, leading to negative consequences for the individual, their families, and society. The pilot project indicates that guided internet-based treatment is an effective treatment that is easily accessible and cost-effective. Access to eBA can help circumvent shame and stigma, increase access to treatment, reduce alcohol use, and improve physical and mental health.
Individuals who wish to participate in eBA do not need a referral from a GP. After an initial screening, participants will be given access to eBA, which consists of 9 treatment modules to be completed over an 8-12-week period, upon giving their consent. Participants will be followed up 4 weeks, 6 months, and 2 years after the completion of treatment. Data will be collected during screening, throughout the treatment period, and post-treatment. Data will be collected in the form of questionnaires, interviews, and registry data.
Simultaneously with the implementation of eBA as an experimental treatment, this project aims to investigate the characteristics of participants who apply for eBA, as well as examine the effects eBA may have in terms of reducing alcohol use, improving physical and mental health, and enhancing the quality of life among participants. The overarching goal of the study is to strengthen the understanding of the effects of internet-based treatment, thereby providing a sufficient basis to assess whether eBA should be implemented as a regular treatment option.
The study will also be part of a larger collaborative project where we will conduct meta-analyses of results from eBA and two other studies that also include treatment programs aimed at individuals with varying degrees of alcohol problems: the "Predictor Study" and "Endre". The three treatment programs are aimed at individuals who are at different stages in their problem trajectory. The goal of this collaborative project is to contribute to the development of a more holistic and targeted treatment offer for individuals with varying degrees of problem development.
Eligibility
Primary outcome measure(s)
- Identifying characteristics of people seeking eBA — Baseline measure
Describe demographics, age, sex, education, occupation, main source of income, marital status, children, duration of problem, previous treatment experience - Changes in alcohol use — Measure changes from baseline to end of treatment, and 6 months and 2 years post-treatment
Measure changes using the Alcohol Use Disorder Scale (AUDIT ), reporting on a sum score scale from 0 to 40; higher score indicate worse outcome. - Changes in mental health status — Measure changes from baseline to end of treatment, and 6 months and 2 years post-treatment
Measure changes in SCL-10R (Symptom Check List) scores on a scale from 1 to 4, the higher score the wore outcome. - Changes in mental health status — Measure changes from baseline to end of treatment, and 6 months and 2 years post-treatment
Measure changes using GAD-7 (Generalized Anxiety Disorder), reporting on a scale from 0 to 3; higher score indicating worse outcome. - Changes in quality of life — Measure changes from baseline to end of treatment, and 6 months and 2 years post-treatment
Measure changes in 5Q-5D-5L (quality of life ), including av visual analoge scale (VAS). The 5Q-5D-5L scores on a scale from 1 to 5, were high score indicate worse outcome. The instrument includes a VAS from 0 to 100, where higher score indicate better outcome. - Changes in quality of life — Measure changes from baseline to end of treatment, and 6 months and 2 years post-treatment
Measure changes in WHO quality of life score (WHOQOL-1) on a scale from 1 to 5, where higher scores indicate better outcome.
Trial sites (5)
| Facility | City | Region | Status |
|---|---|---|---|
| Sørlandet Hospital Trust (Hospital of Kristiansand) | Kristiansand | Agder | |
| Akershus University Hospital | Loerenskog | Akershus | |
| Innlandet Hospital Trust | Lillehammer | Innlandet | |
| St. Olavs Hospital | Trondheim | Trøndelag | |
| Vestfold Hospital Trust | Tønsberg | Vestfold |
More Sykehuset i Vestfold HF trials in Norway
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06739109 on ClinicalTrials.gov ↗ ← All trials in Norway